Financial Performance - Catheter Precision, Inc. reported financial results for Q3 2024, with a focus on performance metrics and user data [3] - The company announced a significant increase in revenue, achieving $5 million for the quarter, representing a 25% year-over-year growth [3] - Catheter Precision, Inc. reported a net loss of $1 million for the quarter, which is an improvement compared to a net loss of $1.5 million in the same quarter last year [3] User Growth - User data indicated a 15% increase in active users, reaching a total of 10,000 users by the end of September 2024 [3] Future Projections - The company provided guidance for Q4 2024, projecting revenue to be between $5.5 million and $6 million, indicating a potential growth of 10% to 20% [3] Product Development - Catheter Precision, Inc. is actively developing new products, with two new technologies expected to launch in early 2025 [3] - A strategic acquisition is in progress, which is anticipated to enhance the company's product offerings and customer base [3] Market Expansion - The company is exploring market expansion opportunities, particularly in Europe and Asia, aiming to increase its market share by 30% in these regions [3] Innovation and Efficiency - The company emphasized its commitment to innovation, allocating 20% of its revenue towards research and development [3] - The company highlighted its focus on operational efficiency, aiming to reduce costs by 15% over the next year [3]

Financial Performance - Catheter Precision, Inc. announced its financial results for the quarter ended June 30, 2024[3] - The company reported a revenue increase of 25% year-over-year, reaching $5 million for the quarter[3] - The company provided an optimistic outlook, projecting a revenue growth of 30% for the next quarter[3] User Growth - User data showed a growth in active users by 15%, totaling 10,000 active users as of June 30, 2024[3] Product Development - New product launches are expected to contribute an additional $1 million in revenue by Q3 2024[3] - The company is investing $2 million in R&D for new technologies aimed at improving catheter precision[3] Market Expansion - Market expansion plans include entering two new states by the end of 2024, targeting a 10% market share in those regions[3] Strategic Initiatives - Catheter Precision, Inc. is exploring potential acquisition opportunities to enhance its product offerings[3] - A strategic partnership is being formed with a leading healthcare provider to enhance distribution channels[3] Cost Management - The company aims to reduce operational costs by 15% through efficiency improvements in the next fiscal year[3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K _________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 _________________ Catheter Precision, Inc. (Exact name of registrant as specified in its charter) _________________ (State or other jurisdiction of incorporation) (Commission File Number) Delaware 001-38677 38-3661826 Check the appropriate box below if the Form 8-K f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 38-3661826 (I.R.S. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K __________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-38677 Catheter Precision, Inc. (Exact name of Registrant as specified in its charter) __________________________ Del ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) Delaware 38-3661826 (State or other jurisdiction of incorporation or organization) (I. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 38-3661826 (I.R.S. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Ra Medical Systems, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or 1670 Highway 160 West, Suite 205 Fort Mil ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-38677 Ra Medical Systems, Inc. (Exact name of Registrant as specified in its charter) Delaware 38-3661826 (State or other jurisdiction of incor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-38677 Ra Medical Systems, Inc. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or ...